Piperacillinsodium 1000 Mg +tazobactum125 Mg Injection

Piperacillinsodium 1000 Mg +tazobactum125 Mg Injection – PIPCHEM-TAZ-1.125 Injection is a broad-spectrum antibiotic combination developed by Swisschem Healthcare for the treatment of severe and complicated bacterial infections. It contains Piperacillin Sodium 1000 mg, a penicillin-class antibiotic that inhibits bacterial cell wall synthesis, and Tazobactam 125 mg, a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation. This synergistic action enhances the effectiveness of the antibiotic against resistant bacteria. The injectable formulation ensures a rapid onset of action, making it suitable for hospital and critical care settings. PIPCHEM-TAZ-1.125 is widely used in managing serious infections where prompt and reliable antibacterial therapy is essential.

Medical Uses

• PIPCHEM-TAZ-1.125 Injection is used to treat severe bacterial infections in various body systems.
• It is effective in respiratory tract, urinary tract, and intra-abdominal infections.
• The injection is used for skin and soft tissue infections.
• It helps manage hospital-acquired infections and complicated cases.
• It supports rapid infection control in critical care settings.

Directions to Use

• PIPCHEM-TAZ-1.125 Injection should be administered by a qualified healthcare professional.
• It is given intravenously or intramuscularly as prescribed.
• Dosage depends on infection severity and patient condition.
• Proper dilution and administration techniques must be followed.
• Complete the full course to ensure effective bacterial eradication.

Precautions

• Use this medication cautiously in patients with a history of penicillin or beta-lactam allergy.
• Inform your doctor about kidney or liver disorders before use.
• Monitor renal function during prolonged therapy.
• Avoid unnecessary or prolonged use to reduce resistance risk.
• Use during pregnancy only if clearly indicated.

Possible Side Effects

• Mild gastrointestinal disturbances such as nausea or diarrhea may occur.
• Injection site reactions like pain or redness may be observed.
• Allergic reactions such as rash or itching may develop.
• Rarely, electrolyte imbalance or kidney function changes may occur.
• Seek immediate medical attention for severe reactions.

Frequently Asked Questions

Q: How does the presence of Tazobactam in the compounds present in the formulation of PIPCHEM-TAZ-1.125 enhance the effectiveness of Piperacillin?

A: Tazobactam inhibits beta-lactamase enzymes, which are produced by resistant bacteria, and it allows Piperacillin to work effectively against a broader range of infections.

Q: Why is Swisschem Healthcare’s PIPCHEM-TAZ-1.125 injectable considered suitable for hospital use?

A: The formulation used in PIPCHEM-TAZ-1.125 contains a high-quality sterile formulation that provides a consistent potency, and due to its reliability to manage severe infections, it highly used injectable for the treatment of severe and complicated bacterial infections and thus it is widely used in clinical settings.

Q: Do healthcare professionals recommend PIPCHEM-TAZ-1.125 injectable for multidrug-resistant infections?

A: Yes, it is often prescribed by healthcare professionals for resistant infections, depending on bacterial sensitivity and clinical evaluation.

Q: Why is it strictly advised to complete the prescribed treatment course of this antibiotic, even when the condition becomes better?

A: It is advised to complete the full course as it ensures the complete eradication of bacteria and also reduces the risk of resistance development.

Q: Why does a healthcare professional adjust dosage in patients with kidney impairment?

A: It is required as it prevents accumulation and ensures safe therapeutic levels.

Q: Is it safe to use this injection in combination with other antibiotics?

A: Yes, it is often prescribed by healthcare professionals for the treatment of severe infections under medical supervision.

Q: How much duration does PIPCHEM-TAZ-1.125 injection take after administration to start working?

A: It generally starts acting the moment this injection is administered to a patient. For clinical improvement, the duration of the condition getting better may depend on infection severity and patient response.